calprotectin Archives - Page 2 of 7 - Buhlmann Diagnostics Corp

Tag: calprotectin

Interview: BUHLMANN fCAL ELISA in a Clinical Laboratory- Expert User Perspectives

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 In this Video You will Learn: Background information on calprotectin and it’s use in primary care Technical details of calprotectin testing in the laboratory Perspectives and general tips on the use of the BÜHLMANN fCAL® ELISA Contact our team and learn more about
Continue Reading

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

IBDoc® Citation: Wei, S. , Tung, C. et al.  Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research 2018;16(4):546-553. DOI: https://doi.org/10.5217/ir.2018.00052 PMID: 30301339 Highlights from this Publication “96% of the patients were satisfied with the home test..." “71% of patients preferred the home test method monitor
Continue Reading

LabSense News Fall 2018 Edition

Continue Reading

IBDoc® Talk – Tips and Tricks Teleconference

Health Canada Licence: 98903, Device class: 3  BÜHLMANN IBDoc® is not available for sale in the US. IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. IBDoc® allows IBD patients convenient self-testing of fecal calprotectin. Teleconference Overview Goal of Discussion The goal was for Clinical Administrators and Clinical Users from
Continue Reading

Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease.

BÜHLMANN fCAL® ELISA Citation Pavlidis, P. et al., 2016, Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease, Scandinavian Journal of Gastroenterology.  PMID: 27400728  DOI: 10.1080/00365521.2016.1205128 Highlight from this Publication “The ΔFCAL could act as an ‘early warning’ to consider alternatives such as dose optimisation or another biologic with a different mode of action,
Continue Reading

Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study.

BÜHLMANN fCAL® ELISA Citation Lasson, A. et al., 2014, Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of relapse: A prospective, randomized, controlled study, United European Gastroenterology Journal.  PMID: 25653861 DOI: 10.1177/2050640614560785 Highlight from this Publication “In patients with UC, FC-guided dosing of the patient’s 5-ASA agent showed significantly lower relapse rates than
Continue Reading

BUHLMANN LabSense News Summer 2018 Edition

In this "Summer Edition" we are pleased to announce the FDA 510 (k) clearance of the BÜHLMANN fCAL® ELISA. We make mention of upcoming meetings where you can find us such as American Association of Clinical Chemistry (AACC) and the Association of Medical Laboratory Immunologists (AMLI) annual meetings. Additionally, we share the exciting happenings pertaining to
Continue Reading

First IBD Nurse Led IBDoc Study

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Pearl Avery, UK IBD Nurse of the year, shares her first experience using IBDoc® in clinical practice. She explains the study she published at ECCO 2018 in Vienna in this video. Highlight from this Poster   "The BÜHLMANN IBDoc® adds
Continue Reading

BÜHLMANN Laboratories AG Receives FDA Clearance for its fCAL® ELISA Calprotectin Test

BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. Amherst NH, June 12, 2018: BÜHLMANN Laboratories AG, is proud to announce it has received United States Food and
Continue Reading

IBDoc and Me

Health Canada Licence: 98903, Device class: 3  IBDoc® is not available for sale in the US. Read perspectives and insights from a patient from the UK who has been using IBDoc®  since last October and is trying this new tool to monitor his Crohn’s Disease.  He has been documenting his experiences in a blog to share his
Continue Reading